Elevance Health, Inc. (ELV) company profile
Close on Nov 17, 2026Market cap $93.75BP/E 18.5Yield –
About Elevance Health
Hospital & Medical Service Plans, SIC 6324
Elevance Health delivers integrated health solutions spanning medical, pharmacy, and behavioral health services. The enterprise operates across four primary segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. Product offerings include risk-based network plans like PPOs and HMOs, fee-based administrative solutions, pharmacy management, and specialty options such as dental, vision, stop loss, and supplemental coverage. Customers include individual consumers, small and large employer groups, and participants in federal and state-sponsored Medicare and Medicaid programs.
The organization serves approximately 45.2 million medical members across the United States through its affiliated health plans as of December 31, 2025. It holds Blue Cross and Blue Shield licenses covering fourteen individual states and operates non-BCBS brands like Wellpoint, MMM, and Simply Healthcare across multiple regions. Subsidiaries maintain insurance operating licenses in all fifty states, the District of Columbia, and Puerto Rico. The company's headquarters location is not specified in the provided business disclosure text.
Summary of the business section of Elevance Health's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Elevance Health, Inc.
- Founded
- 1940
- Headquarters
- Indianapolis, IN
- Address
- 220 Virginia Avenue 46204
- Phone
- (800) 331-1476
- Website
- www.elevancehealth.com
- Employees
- 97,100, Dec 31, 2025
- Industry
- Hospital & Medical Service Plans
- Incorporated in
- Indiana
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Indianapolis, Indiana
Stock & identifiers
- Ticker
- ELV
- Former tickers
- ANTM until Jun 28, 2022; WLP until Feb 24, 2015
- Exchange
- NYSE
- IPO date
- Oct 30, 2001
- Shares outstanding
- 216M, Oct 15, 2026
- Public float
- $87.35B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Jun 1, 2005
- SEC CIK
- 1156039
- CUSIP
- 036752103
- ISIN
- US0367521038
- FIGI
- BBG000BCG930
- Share class FIGI
- BBG001S6KBQ8
- LEI
- 8MYN82XMYQH89CTMTH67
- EIN
- 35-2145715
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Gail Boudreaux | President and CEO, Director | 172,036 |
| Ratnakar Lavu | EVP & Chief Digital Info Ofr | 14,849 |
| Mark Kaye | EVP & CFO | 19,919 |
| Erin M. Wessling | EVP & Chief Legal Officer | 7,230 |
| Ryan R. Craig | EVP & Chief HR Officer | 6,530 |
| Ronald W. Penczek | CAO & Controller | 3,740 |
| Charles Morgan Kendrick JR | EVP & President, Commercial | 11,791 |
| Peter D. Haytaian | EVP & Pres Carelon & CarelonRx | 27,222 |
| Felicia F. Norwood | EVP &Chief Health Benefits Ofr | 38,838 |
| Blair Williams Todt | EVP, CLO & CAO | 15,631 |
| Ramiro G. Peru | Director | 10,908 |
| Robert L. Dixon JR | Director | 10,734 |
| Amy W. Schulman | Director | 781 |
| Antonio F. Neri | Director | 5,488 |
| Ryan M. Schneider | Director | 7,163 |
| Lewis Hay Iii | Director | 12,070 |
| Steven H. Collis | Director | 4,202 |
| Deanna D. Strable-Soethout | Director | 2,209 |
| Susan D. DeVore | Director | 4,065 |
| Bahija Jallal | Director | 5,351 |
| R. Kerry Clark | Director | 9,640 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $22.58M | $18.79M | $7.21M | $117 | $148 |
| FY2024 | $20.47M | -$3.96M | $6.33M | $121 | $129 |
| FY2023 | $21.89M | $16.22M | $8.92M | $152 | $126 |
| FY2022 | $20.93M | $35.26M | $6.71M | $163 | $124 |
| FY2021 | $19.35M | $50.43M | $6.45M | $146 | $126 |
| FY2020 | $17.11M | $28.32M | $5.39M | $108 | $113 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Gail Boudreaux President and Chief Executive Officer (CEO) | $1.60M | $13.44M | $4.20M | $2.77M | $574.27K | $22.58M | +10% |
| Mark Kaye EVP and Chief Financial Officer (CFO) | $938.46K | $4.56M | $1.42M | $974.12K | $94.48K | $7.99M | +16% |
| Peter Haytaian EVP and President, Carelon and CarelonRx | $950.00K | $3.84M | $1.20M | $986.10K | $122.37K | $7.10M | +12% |
| Felicia Norwood EVP and Chief Health Benefits Officer | $950.00K | $3.84M | $1.20M | $986.10K | $97.85K | $7.07M | +12% |
| Morgan Kendrick EVP and President, Commercial and Specialty Health Benefits | $888.46K | $3.60M | $1.12M | $922.22K | $126.18K | $6.66M | +15% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, our employee population, including all full-time, part-time and temporary workers, consisted of approximately 97,100 individuals, 71,900 in the United States and 25,200 internationally.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?